This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Novelli, V.
Right arrow Articles by Holzel, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Novelli, V.
Right arrow Articles by Holzel, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 1955-1960, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Safety and Tolerability of Fluconazole in Children

Vas Novelli1 and Helen Holzel2

Infectious Diseases Unit1 and Department of Medical Microbiology,2 Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

Received 14 January 1998/Returned for modification 19 April 1998/Accepted 26 May 1999

The safety profile of fluconazole was assessed for 562 children (ages, 0 to 17 years) comprising 323 males and 239 females. The data are derived from 12 clinical studies of fluconazole as prophylaxis or treatment for a variety of fungal infections in predominantly immunocompromised patients. Most children received multiple doses of fluconazole in the range of 1 to 12 mg/kg of body weight; a few received single doses. Administration was mainly by oral suspension or intravenous injection. Overall, 58 (10.3%) children reported 80 treatment-related side effects. The most common side effects were associated with the gastrointestinal tract (7.7%) or skin (1.2%). Self-limiting, treatment-related side effects affecting the liver and biliary system were reported in three patients (0.5%). Overall, 18 patients (3.2%) discontinued treatment due to side effects, mainly gastrointestinal symptoms. Dose and age did not appear to influence the incidence and pattern of side effects. Treatment-related laboratory abnormalities were uncommon, the most frequent being transient elevated alanine aminotransferase (4.9%), aspartate aminotransferase (2.7%), and alkaline phosphatase (2.3%) levels. Although 98.6% of patients were taking concomitant medications, no clinical or laboratory interactions were observed. The safety profile of fluconazole was compared with those of other antifungal agents, mostly oral polyenes, by using a subset of data from five controlled studies. Side effects were reported by more patients treated with fluconazole (45 of 382; 11.8%) than by those patients treated with comparable agents (25 of 381; 6.6%); vomiting and diarrhea were the most common events in both groups. The incidence and type of treatment-related laboratory abnormalities were similar for the two groups. In conclusion, fluconazole was well tolerated by the pediatric population, many of whom were suffering from severe underlying disease and were taking a variety of concurrent medications. The safety profile of fluconazole in children mirrors the excellent safety profile seen in adults.

Antimicrobial Agents and Chemotherapy, August 1999, p. 1955-1960, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Thurey, J., Molyneux, E. (2008). Evidence behind the WHO Guidelines: Hospital Care for Children: The Usefulness of Azole Prophylaxis against Cryptococcal Meningitis in HIV-positive children. J Trop Pediatr 54: 361-363 [Full Text]  
  • (2007). Recurrent tinea versicolor: treatment with itraconazole or fluconazole?. Arch. Dis. Child. 92: 1040-1042 [Full Text]  
  • Blyth, C. C., Palasanthiran, P., O'Brien, T. A. (2007). Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review. Pediatrics 119: 772-784 [Abstract] [Full Text]  
  • Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B., Pedicone, L. (2007). Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection. Antimicrob. Agents Chemother. 51: 812-818 [Abstract] [Full Text]  
  • Uko, S., Soghier, L. M., Vega, M., Marsh, J., Reinersman, G. T., Herring, L., Dave, V. A., Nafday, S., Brion, L. P. (2006). Targeted Short-Term Fluconazole Prophylaxis Among Very Low Birth Weight and Extremely Low Birth Weight Infants. Pediatrics 117: 1243-1252 [Abstract] [Full Text]  
  • Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., Lortholary, O. (2006). Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?. J Antimicrob Chemother 57: 384-410 [Abstract] [Full Text]  
  • Manzoni, P., Arisio, R., Mostert, M., Leonessa, M., Farina, D., Latino, M. A., Gomirato, G. (2006). Prophylactic Fluconazole Is Effective in Preventing Fungal Colonization and Fungal Systemic Infections in Preterm Neonates: A Single-Center, 6-Year, Retrospective Cohort Study. Pediatrics 117: e22-e32 [Abstract] [Full Text]  
  • Chetwynd, E. M., Ives, T. J., Payne, P. M., Edens-Bartholomew, N. (2002). Fluconazole for Postpartum Candidal Mastitis and Infant Thrush. J Hum Lact 18: 168-171 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»